UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
  
FORM 8-K
  
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): May 25, 2017

INDIA GLOBALIZATION CAPITAL, INC.
(Exact name of registrant as specified in its charter)
 
Maryland
001-32830
20-2760393
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)

4336 Montgomery Ave., Bethesda, Maryland   20814
(Address of principal executive offices)         (Zip Code)

(301) 983-0998
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1934 (§240.12b-2 of this chapter)
Emerging growth company ☐.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Item 8.01        Other Events.
 
India Globalization Capital, Inc. (the “Company”) (NYSE MKT: IGC), has released an “Executive Summary”.  The “Executive Summary” contains previously undisclosed information about the Company’s product portfolio, as well as forward looking statements about the Company’s plans.  Because shares of the Company trade on the Borse Frankfurt (Xetra-2) exchange in Germany, under the symbol IGS1, a German language version of the “Executive Summary” will also be made available on the Company’s website.
 
A copy of the Executive Summary is filed as Exhibit 99.1 to this Form 8-K and is incorporated by reference into this Item 8.01 in its entirety.

Cautionary Statement Pursuant to Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995:

“Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995:  This report contains forward-looking statements identified by the use of words such as should, believes, plans, goals, expects, may, will, or the negatives thereof, and other variations thereon or comparable terminology.  Such statements are based on currently available information, which management has assessed but which is dynamic and subject to rapid change due to risks and uncertainties that affect our business. Our success is highly correlated with the success of our product candidates. We may not be able to protect our intellectual property adequately, or receive patents. We may not receive regulatory approval for our products, or trials.  We may not have adequate resources including financial resources to successfully conduct the requisite trials.  We may not be able to successfully commercialize our products even if they are successful and receive regulatory approval. Our projections anticipate stable pricing, which may not hold out over the next several years.  Failure or delay with respect to any of the factors above could have a material adverse effect on our business, future results of operations, our stock price, and our financial condition. These and other risks are detailed from time to time in our filings with the U.S. Securities and Exchange Commission.  Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be forward-looking statements.  Forward-looking statements involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated.
 
Item 9.01        Financial Statements and Exhibits.
 
(d)                     Exhibits.
 
The exhibit listed in the following Exhibit Index is filed as part of this current report.
 
Exhibit
Number                 Exhibit Description
99.1                         IGC Executive Summary, dated May 25, 2017.
 
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
India Globalization Capital, Inc.
 
 
 
 
Date: May 25, 2017
By:
/s/  John Cherin            
 
 
 
John Cherin
 
 
 
Chief Financial Officer, Treasurer,
and Principal Accounting Officer
 
 
 
 
 
 
 
 
 
Exhibit Index
 
 
99.1
 
 
 


Exhibit 99.1
 
 
The IGC Executive Summary, dated May 25, 2017 can be viewed in PDF format by clicking here: ex99-1.pdf
 
 A Leader in Cannabis-Based Combination Therapies
NYSE MKT: IGC

EXECUTIVE SUMMARY

MISSION STATEMENT
Develop, patent, test, and commercialize cannabis-based pharmaceutical, nutraceutical, and veterinary medicines.

OPPORTUNITY
Cannabis molecules (THC, CBD, CBN, CBG, terpenes etc.) activate over 60 known molecular pathways in the human body. Legal complications and misunderstanding have led to a vacuum in research and development, creating openings for biopharma entrepreneurs to occupy. Opportunities exist for breakthroughs in the treatment of pain, neurological disorders, eating disorders, and mood disorders using cannabis molecules.

STRATEGY
•
We are pursuing a unique strategy that reduces regulatory approval time and development costs while generating compelling revenue opportunities.
•
Rather than attempting full novel drug applications (which require 7-9 years and 100s of millions of dollars to secure FDA approval), we are developing cannabis based drugs in three categories:
–  Combination therapy
–  Veterinary drugs
–  Multiple-end point, symptom reducing and disease modifying nutraceuticals.
                                    
•
Because our chosen categories face lower regulatory burdens, some of our products could be commercialized after trials lasting only 18-24 months at a cost of only $2M-3M per product.
•
Our products maximize revenue potential by targeting diseases that have:
–  Very large market size.
–  Severe unmet pharmaceutical needs.
–  Patients who may need three or four separate products.
–  Highly centralized treatment institutions (enabling targeted sales operations).
–  Prevalence among patients who are likely to be interested in natural alternatives to harsh chemicals (e.g. avoidance of opioids).
 
Some of the most exciting products IGC is developing target the Alzheimer’s, Parkinson’s and pain markets.

Example Revenue Potential Breakdown:
IGC Parkinson’s Suite
Primary Product: IGC-PK1
Targets reduction in:
> Unwanted accelerations
> Anxiety
> REM sleep behavior disorder
·
U.S. Patient Base: 1,000,000 persons
·
Target Penetration: 3% (based on symptom prevalence, high side-effect patients, anecdotal effectiveness, and drug competition)
·
Dosage: 1/day
·
Estimated Unit Price: $30
·
Potential Revenue: $315,000,000/year

Secondary Parkinson’s Products
Localized stiffness and pain alleviator (IGC-PKp1)
Potential Revenue: $65,000,000/year
Quick release stammering alleviator (IGC-PKs1)
Potential Revenue: $70,000,000/year
Drooling alleviator (IGC-PKd1)
Potential Revenue: $85,000,000/year
WHERE DID IGC START?
We have been developing patentable cannabinoid products since 2014, focusing on combination therapy and veterinary medicine.

WHERE IS IGC RIGHT NOW?
·
We are a world leader in cannabis-based combination therapy.
·
We have one of America’s leading cannaceutical product pipelines and potential intellectual property footprints.
·
We have 10 human and veterinary cannaceutical products currently in development across many disease areas including epilepsy, PTSD, cachexia, pain, Parkinson’s, and Alzheimer’s. We have filed six patents for these therapies.
 
WHERE IS IGC GOING?
·
We aspire to be part of the Big Four of cannabis companies (GWPH, ZYNE, INSY, IGC)
·
We plan to have several FDA approved cannabis pharmaceutical therapies.
·
We hope to be among the first companies with FDA labeling rights for nutraceutical cannabis products.
·
We expect to commercialize product suites with revenue potential between $100M and $500M.
·
We plan to commence revenue in mid 2019.
 
ONE-YEAR GOALS
·
Occupy many prime segments of the cannaceutical intellectual property universe (15- 20 patent filings/licensing).
·
Finalize R&D for pain, Alzheimer’s, and Parkinson’s suites.
·
Begin clinical trials for at least two products for nutraceutical or veterinary approval and commercialization (>$200M revenue potential/ product).
·
Advance first and second choice products towards low clinical trial burden FDA application.
 
COMPARATIVE VALUATION
IGC is on the NYSE MKT. Companies trading on OTC with much smaller product pipelines have similar valuations while those with similar sized pipelines have much higher valuations.
Nemus Bioscience (OTC: NMUS) $9.1M
India Globalization Capital (NYSE MKT: IGC) $11M
PharmaCyte Biotech (OTC: PMCB) $58M
Axim Biotechnologies Inc. (OTC: AXIM) $401M
 

 


This regulatory filing also includes additional resources:
ex99-1.pdf